

PARTNER 3 Trial - Aortic Valve-in-Valve

NCT03003299

Status	RECRUITING
Phase	Not Applicable
Sponsor	Edwards Lifesciences
Enrollment	125 participants

Key Eligibility Criteria

Inclusion (6)

- Failing surgical or transcatheter bioprosthetic valve in the aortic position demonstrating e moderate stenosis and/or e moderate insufficiency.
- Bioprosthetic valve with a true internal diameter (True ID) of 18.5 mm to 28.5 mm.
- NYHA Functional Class e II.
- Heart Team agrees the patient is low to intermediate risk.
- Heart Team agrees valve implantation will likely benefit the patient.

... and 1 more (see full listing online)

Exclusion (31)

- Surgical or transcatheter valve in the mitral position (mitral rings are not an exclusion)
- Severe regurgitation (> 3+) or stenosis of any other valve
- Failing valve has moderate or severe paravalvular regurgitation
- Failing valve is unstable, rocking, or not structurally intact
- Increased risk of coronary obstruction by prosthetic leaflets of the failing valve.

... and 26 more (see full listing online)

Locations (51 total)

Banner University Medical Center, Phoenix, Arizona, United States
University of California Los Angeles, Los Angeles, California, United States
Sutter Medical Center, Sacramento, California, United States

... and 48 more locations